Application of Anti-tetanus toxin antibody in preventing or treating tetanus

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By developing the recombinant natural all-human monoclonal antibody TRN0011, the problems of hypersensitivity reaction, long immune cycle and short immune function maintenance time of existing tetanus passive immune preparations have been solved, and faster and longer-term antibody protection effects have been achieved.

WO2025067058A1 Publication Date: 2025-04-03ZHUHAI TRINOMAB PHARMACEUTICAL CO LTD

5 Cites 0 Cited by

Patent Information

Application Number: PCT/CN2024/119974
Authority / Receiving Office: WO · WO
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2023-09-27
Filing Date: 2024-09-20
Publication Date: 2025-04-03

Application Information

Patent Timeline

27 Sep 2023

Priority

20 Sep 2024

Application

PCT/CN2024/119974

03 Apr 2025

Publication

WO2025067058A1

IPC: A61K39/40; A61K39/395; C07K16/12; A61P31/04; A61P21/02

CPC: A61P21/02; A61P31/04; C07K16/1282; C07K2317/76; A61K2039/505; C07K2317/90; A61K2039/545; A61K2039/54

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

AI Tagging

Application Domain

Antibacterial agents Immunoglobulins against bacteria

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

The existing passive immune preparations of tetanus have problems such as hypersensitivity reactions caused by animal-derived materials, long immune cycles, application disorders, risk of infectious diseases and short maintenance time for immune effects.

Method used

Developed a recombinant natural all-human monoclonal antibody against tetanus toxin, TRN0011, to provide longer antibody protection by binding to tetanus toxins through high affinity.

Benefits of technology

TRN0011 can reach the antibody protection level in a shorter time, maintain longer, have higher antibody titers, and have good safety and tolerance, making it suitable for large-scale production.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

Provided is an application of an anti-tetanus toxin antibody in preventing or treating tetanus. The anti-tetanus toxin antibody is applied in a specific administration regimen, and can achieve the technical effects of being quicker to take effect and having a longer protection time than existing passive immunization agents, and can therefore effectively prevent or treat tetanus.

Need to check novelty before this filing date? Find Prior Art